TS
NBIX icon

Triglav Skladi’s Neurocrine Biosciences NBIX Stock Holding History

Triglav Skladi’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Hold
9,000
– – 0.08% 122
2026
Q1 		$1.19M Sell
9,000
-1,000
-10% -$133K 0.08% 113
2025
Q4 		$1.42M Sell
10,000
-1,000
-9% -$145K 0.09% 114
2025
Q3 		$1.54M Hold
11,000
– – 0.1% 92
2025
Q2 		$1.38M Hold
11,000
– – 0.1% 98
2025
Q1 		$1.22M Hold
11,000
– – 0.1% 94
2024
Q4 		$1.5M Buy
+11,000
New +$1.36M 0.12% 87

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Triglav Skladi's NBIX Position: Q2 2026 in Review

Triglav Skladi held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 9,000 shares worth $1.52M. The position accounts for 0.08% of the portfolio, ranked #122.

Triglav Skladi first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.54M in Q3 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Triglav Skladi held 9,000 shares of Neurocrine Biosciences worth $1.52M as of Q2 2026.
  • Triglav Skladi left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.08% of Triglav Skladi's portfolio in Q2 2026, its #122 holding.
  • Triglav Skladi first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Triglav Skladi's Neurocrine Biosciences position peaked at $1.54M in Q3 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Triglav Skladi's 13F filing for Q2 2026, filed 11 Aug 2026.